Compare Abeona Therapeutics Inc (ABEO) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Broadcom Inc — how do they compare? Abeona Therapeutics Inc trades at $7.53 (market cap $421.19M), while Broadcom Inc trades at $417.11 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 4701× Abeona Therapeutics Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AVGO | |
|---|---|---|
Market Cap | $421.19M | $1.98T |
Sector | Health | Technology |
52-Week High | $7.45 | $481.57 |
52-Week Low | $4.17 | $289.60 |
Enterprise Value | $276.10M | $2.02T |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Broadcom (AVGO) trades at $419.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong support at $412. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 estimate. Revenue grew to $63.89 billion in 2025, and net income surged to $23.13 billion, reflecting a 36.19% margin. Analysts maintain a strong buy consensus, with a $510.21 price target, citing AI-driven growth prospects.
The outlook for AVGO remains positive, driven by AI semiconductor demand and solid cash flow generation. However, high valuation multiples like a P/E of 69.23 pose risks if growth slows. Competitive pressures in the chip industry and macroeconomic volatility could challenge future performance, but institutional confidence and consistent earnings strength support a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
